Answers are grounded in this paper and cite their sources.
Primary aldosteronism (PA) is caused by autonomous aldosterone overproduction and characterised by uncontrolled hypertension. There are currently no treatments that target aldosterone synthesis. We evaluated the safety and efficacy of a novel aldosterone synthase inhibitor, dexfadrostat phosphate, in patients with PA.
No takes yet. Share an insight, caveat, or question.
Mulatero et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: